Drugs / ZN-c5
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04852419 | May 2021 → Jun 2022 | breast cancer | Zentera Therapeutics HK Limited | Completed | No outcome recorded |
| Phase 1 | NCT04514159 | Nov 2020 → Oct 2022 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04561752 | Nov → Dec 2020 | — | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04176757 | Jan 2020 → Apr 2021 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03560531 | Nov 2018 → Apr 2022 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZN-c5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176757 ↗ |
| Route | Oral | “ZN-c5 administered orally” NCT03560531 ↗ |